Lung cancer screening pathway integration matures
Low-dose CT screening adoption growth, AI-assisted nodule management, blood-based biomarker integration, and primary-care pathway formalisation are restructuring lung cancer screening.
Lung cancer screening with low-dose CT has been recommended for high-risk populations for years but uptake has been substantially lower than in colorectal or breast cancer screening. AI-assisted nodule management tools have approval and growing adoption, blood-based biomarker programs (multi-cancer early detection assays, lung-specific biomarker programs) are widening, and primary-care pathway formalisation is emerging as the addressable-population enabler. The diagnostic-and-screening pathway integration is the structural commercial enabler that defines downstream lung cancer therapy reach.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- SnapshotAdult diffuse glioma therapy reference (2026)
- ExplainedWhat is glioblastoma?